Does BCBS Cover Wegovy? 2026 Coverage & Costs

Searching by the abbreviation usually means you want speed: does the card in your hand pay for Wegovy, what does it take, and what's the number. Here's the fast, complete version.

Many BCBS plans cover Wegovy in 2026 with prior authorization, and on Caremark-managed Blues it holds preferred status over Zepbound. Coverage requires your plan to include the weight-management benefit, which several Blues cut for fully insured groups this year (Michigan in January 2026, Massachusetts similarly), while self-funded employer plans choose independently. Standard criteria: BMI of 30 or higher, or 27 or higher with a weight-related condition, lifestyle-program documentation, and renewals at 5 percent weight loss. Wegovy's heart-protection approval adds a route for cardiac patients that bypasses weight-loss exclusions.

Below: verify your plan fast, the criteria in detail, costs, and the two backup paths.

Step One: Decode Your BCBS Plan in One Call

Your card names your issuing Blue (Anthem, Highmark, CareFirst, Florida Blue, and Premera are all Blues), and that company's formulary governs you regardless of where you live now. Call the pharmacy number and ask three questions: Does my plan include weight-management drugs? Is Wegovy on formulary and at what tier? What does prior authorization require?

Ask HR a fourth question: is our plan self-funded? Fully insured members in restricting states inherited the 2026 cuts; self-funded members answer to their employer's drug list instead, and benefits teams add the category at renewal more often now that capped-copay structures limit their exposure.

BCBS Prior Authorization Criteria for Wegovy

The clinical gate follows the FDA label across Blues: a BMI of 30 or higher qualifies alone, while 27 to 29.9 needs at least one weight-related condition such as hypertension, prediabetes, dyslipidemia, or obstructive sleep apnea. Most Blues require documented participation in a reduced-calorie diet and exercise program, commonly 3 to 6 months, and a baseline weight on file.

Renewals run on results: continuation approvals generally require at least 5 percent weight loss from baseline during the initial authorization, so every weigh-in belongs in your chart. Submissions with complete BMI, comorbidity, and program documentation clear within 72 hours; gaps create the multi-week denial loops that fill appeal queues.

The Cardiovascular Backup Path

Wegovy carries the FDA's March 2024 approval for reducing cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and a BMI of 27 or higher. Because that indication treats heart disease rather than weight, most Blues evaluate it outside weight-loss exclusions, and it remains available even on plans that cut the weight-management category for 2026.

Qualifying requires a documented prior heart attack, stroke, or peripheral arterial disease. If that's your history, have your prescriber submit under the cardiovascular indication with cardiac records attached; it's the standard Wegovy route on Blue Medicare Advantage plans today and the strongest surviving door in restricting states.

What Wegovy Costs on BCBS in 2026

Covered copays span $25 to $200 monthly across Blue designs, with several Blues adopting flat $200 weight-management copays this year. Novo Nordisk's savings card cuts eligible commercial copays by up to $100 monthly and stacks with most designs. High-deductible members pay negotiated rates until deductibles are met.

Without coverage: NovoCare Pharmacy and major retailers sell Wegovy around $499 monthly, the federal TrumpRx channel lists semaglutide near $350 as it phases in through 2026, and Medicare-eligible members get the $50 copay cap via the cardiovascular route now or the GLP-1 Bridge pilot from July 1, 2026. List price of roughly $1,350 is for nobody.